The stock of Bionano Genomics Inc (BNGO) has seen a 57.95% increase in the past week, with a 28.82% gain in the past month, and a -63.69% decrease in the past quarter. The volatility ratio for the week is 19.92%, and the volatility levels for the past 30 days are at 11.79% for BNGO. The simple moving average for the past 20 days is 30.34% for BNGO’s stock, with a -74.88% simple moving average for the past 200 days.
Is It Worth Investing in Bionano Genomics Inc (NASDAQ: BNGO) Right Now?
The 36-month beta value for BNGO is at 2.14. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for BNGO is 3.00M, and currently, shorts hold a 19.59% of that float. The average trading volume for BNGO on April 16, 2025 was 202.41K shares.
BNGO) stock’s latest price update
Bionano Genomics Inc (NASDAQ: BNGO) has experienced a decline in its stock price by -7.26 compared to its previous closing price of 4.82. However, the company has seen a gain of 57.95% in its stock price over the last five trading days. globenewswire.com reported 2025-04-08 that SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today announced a study published in The Journal of Molecular Diagnostics that describes a method for analysis of multiple myeloma (MM) by optical genome mapping (OGM). MM is one of the most common blood cancers, or hematologic malignancies, and is understood to be a difficult sample to analyze using traditional cytogenetics. Direct analysis of MM samples, by methods such as FISH or OGM, can be problematic because it is challenging to isolate enough cells with a known MM marker (CD138) on their surface, so-called CD138-positive cells. In this paper, researchers at Institute of Medical Genetics, Lille University Hospital, Lille, France, have described a method for OGM that can overcome the hurdle of limited sample quantity and can cut in half the effective CD138-positive cell requirement for analysis by OGM.
Analysts’ Opinion of BNGO
Scotiabank gave a rating of “Sector Outperform” to BNGO, setting the target price at $4 in the report published on January 05th of the previous year.
BNGO Trading at 7.74% from the 50-Day Moving Average
After a stumble in the market that brought BNGO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -93.84% of loss for the given period.
Volatility was left at 11.79%, however, over the last 30 days, the volatility rate increased by 19.92%, as shares surge +35.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.66% lower at present.
During the last 5 trading sessions, BNGO rose by +57.95%, which changed the moving average for the period of 200-days by -89.86% in comparison to the 20-day moving average, which settled at $3.43. In addition, Bionano Genomics Inc saw -74.17% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BNGO
Current profitability levels for the company are sitting at:
- -3.25 for the present operating margin
- 0.01 for the gross margin
The net margin for Bionano Genomics Inc stands at -3.64. The total capital return value is set at -2.54. Equity return is now at value -170.33, with -76.97 for asset returns.
Based on Bionano Genomics Inc (BNGO), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -9.94. The debt to equity ratio resting at 0.2. The interest coverage ratio of the stock is -460.79.
Currently, EBITDA for the company is -97.47 million with net debt to EBITDA at 0.02. When we switch over and look at the enterprise to sales, we see a ratio of 0.32. The receivables turnover for the company is 6.45for trailing twelve months and the total asset turnover is 0.4. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.06.
Conclusion
In conclusion, Bionano Genomics Inc (BNGO) has had a mixed performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
